QIAGEN N.V. QGEN has secured FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, bolstering its syndromic testing portfolio in the United States. This marks the ...
Germantown, Maryland, and Venlo, the Netherlands, June 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Gastrointestinal ...
The QIAstat-Dx panel will provide actionable insights in about one hour, analyzing more than 20 pathogens that cause meningitis / encephalitis syndromes, including bacteria, viruses and yeast and ...
QIAstat-Dx Analyzer 2.0 with Software 1.6 release enables mobile access to test results, streamlining diagnostic processes and enhancing patient care // QIAstat-Dx Analyzer 2.0 also offers enhanced ...
New tests for QIAstat-Dx syndromic solution to distinguish between gastrointestinal pathogens (U.S. submission) and between meningitis and encephalitis infections (CE-IVD registration) Higher-capacity ...
Venlo, the Netherlands, April 24, 2023 (GLOBE NEWSWIRE) -- QIAGEN (QGEN) (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that its QIAstat-Dx syndromic testing solution is expected to be ...
QIAGEN N.V. QGEN recently announced the European launch of its next-generation multiplex gastrointestinal panel — QIAstat-Dx panel. This completely integrated molecular analysis of gastrointestinal ...
Venlo, the Netherlands, March 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the release of the QIAstat-Dx Analyzer 2.0, including the Software 1.6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results